Thus, to further validate CRISPRi screen results, we directly tested 2 of the top sgRNAs that were enriched after selumetinib treatment (T10/T0), RASA2 or KEAP1, which were suppressed in NF1-mutant, PRC2-intact neurofibroma cells using 2 independent sgRNA protospacer sequences (Supplementary Fig. 8e). The gene discussed is KEAP1; the disease is neurofibroma.